Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
2015-003718-25Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of BI 695502 in metastatic colon cancer (mCRC) and colorectal cancer (CRC), sponsored by Boehringer Ingelheim. Primary endpoint: Selected adverse events occurrence. Started Feb 2016; status: completed.
02
Drugs
BI 695502
03
Conditions
metastatic colon cancer (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2015-003718-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003718-25.